Anti-PD1
Dinaciclib induces immunogenic cell death and enhances anti PD1–mediated tumor suppression
... to anti-PD1 ...complement anti-PD1 ...with anti-PD1 Ab and the cyclin-dependent kinase inhibitor dinaciclib in immunocompetent mouse tumor ...of anti-PD1 by ...
12
Targeting tumor intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti PD1 therapy
... mg/kg), anti-PD1 Ab (100 μg/3 injections), and anti-PD1+DON ...and anti-PD1. Additionally, the combination of DON and anti-PD1 resulted in a better survival ...
16
Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury
... of anti-PD1 antibodies, that steroids and other immunosuppressants may have a limited role in treating these particular complications, and that UDCA, cholestyramine and fat-soluble vitamin supplementation ...
9
Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies
... flare or irAE. In another retrospective review [11], Menzies et al. included 119 patients with either underlying auto- immune disease (six with IBD) or major toxicity with ipili- mumab who were being treated with ...
6
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
... to anti-PD1 antibody therapy in NSCLC ...and anti-PD1 treatment failures provide solid evidence to target neutrophils in combination with ICI therapy, which has not been uniformly supported by ...
17
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials
... of PD1 and PD-L1 can suppress the cytotoxic CD8 T-cell mediated immune ...in anti-PD1/anti-PD-L1 immunotherapy in cancer, including head and neck cancer ...to anti- PD1 ...
11
<p>Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway</p>
... obvious T-cell lymphoma in 4 days. Once the tumor appeared, mice were randomly allocated to the two groups (n = 10 each); the treatment group received an intratumoral injection of anti-PD1 (300 µ g) twice ...
10
Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature
... to PD1 inhibition that appeared unusually sensitive, both in terms of susceptibility to autoimmune toxicity and therapeutic ...with anti-PD1/PD-L1 ...
7
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
... to anti-PD-1 monotherapy in this phase 1 study are con- sistent with the hypothesis that high mutation burdens in BCC and CSCC elicit antitumor cellular immunity that could be unleashed by blockade of the ...
5
Combined Trabectedin and anti PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
... and anti-PD-1/PD-L1 mAbs on the other hand. In fact, anti-PD-1 mAb has been reported to show acceptable toxicity profile and encouraging anti- tumor activity in combination with chemotherapy in ...
13
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
... the anti-PD-1 antibody nivolumab with or without the tyrosine kinase inhibitor pazopanib; we found evidence of clinical benefit with a half of the evalu- able patients experiencing a partial response or a stabi- ...
7
A phase II trial of stereotactic body radiotherapy with concurrent anti PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response
... of anti-PD-1 treat- ment by stimulating the accumulation and activation of CD8+ CTLs in the TME ...of anti-PD-1 treatment will precede ...of anti-PD-1 treatment may further stimulate the effec- tor ...
6
Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
... as anti-PD1 or anti-PD-L1 triggers autophagy in tumor cells, which allows the recycling of nutrients and signals by the cells in the vicinity and the release of cytokines and extracellular vesicles ...
5
Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series
... an anti-PD1 agent in combination with another immunotherapeutic ...systemic anti-PD1 therapy, 1 was initially treated with single agent ipilimumab (3 mg/ kg) prior to approval of ...
7
Pharmacodynamics of Pre Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non small cell lung cancer (NSCLC): study protocol for a multicentre, open label, phase 1B/2, translational trial (POPCORN)
... its anti-osteoclastic activity ...including anti-PD1; of note, RANKL blockade alone had minimal single agent effi- cacy [24 – ...exceptional anti-tumour responses have been reported in case ...
9
miRNA Regulation of Programmed Cell Death-1 in T Cells: Potential Prognostic and Therapeutic Markers in Melanoma
... on anti-PD1 antibodies (Nivolumab, Lambrolizumab and Pidilizumab) in various cancers including melanoma have entered stage 2-3 trials since late 2008 [60, ...the PD1 ligand on the tumor cell, which ...
108
Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis
... evaluate anti-PD1 therapy in patients with hepatocellular cancer suggest that these may be safely given to patients with HBV ...of PD1 + T cell subsets in viral ...
5
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
... melanoma. Anti-PD1 therapy was not re- initiated and staging 3 months after the cardiac arrest without any further tumor therapy showed stabilization of ...
11
FUTURE PERSPECTIVES IN MELANOMA RESEARCH Meeting report from the “Melanoma Research: a bridge from Naples to the World Napoli, December 5th–6 th2011”
... as anti-CTLA4, anti-PD1 and IL-2 and for antigen-specific immunotherapy since the fact that the antigen is administered, doesn ’ t mean that immune system “ sees ” only that specific antigen (epitope ...
17
Enhanced effect of checkpoint inhibitors when given after or together with IMM 101: significant responses in four advanced melanoma patients with no additional major toxicity
... the anti-PD1 antibody pembrolizumab and another case of a rapid complete response to treatment when IMM-101 was given in com- bination with the anti-PD1 antibody ...
7